Smith & Nephew PLC
LSE:SN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (10.5), the stock would be worth GBX1 282.15 (2% upside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 10.3 | GBX1 262.5 |
0%
|
| 3-Year Average | 10.5 | GBX1 282.15 |
+2%
|
| 5-Year Average | 11.4 | GBX1 391.28 |
+10%
|
| Industry Average | 0 | GBX2.97 |
-100%
|
| Country Average | 0 | GBX2.4 |
-100%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
GBX12.3B
|
/ |
Jan 2026
$1.6B
|
= |
|
|
GBX12.3B
|
/ |
Dec 2026
$1.8B
|
= |
|
|
GBX12.3B
|
/ |
Dec 2027
$1.9B
|
= |
|
|
GBX12.3B
|
/ |
Dec 2028
$2B
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| UK |
|
Smith & Nephew PLC
LSE:SN
|
10.7B GBP | 10.3 | 22.7 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
166.7B USD | 14.5 | 26.6 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
165.3B USD | 43.9 | 57.9 | |
| US |
|
Stryker Corp
NYSE:SYK
|
129.4B USD | 20.4 | 39.9 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
109.1B USD | 13.1 | 23.6 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
90.4B USD | 18.6 | 31.2 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
43.2B EUR | 11.4 | 20.5 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
47.3B USD | 24 | 44.1 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
46.5B USD | 31 | 43.9 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
45.2B USD | 10.1 | 25.7 | |
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
33.8B USD | 11.6 | 16.2 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0 |
| Median | 0 |
| 70th Percentile | 0 |
| Max | 743.2 |
Other Multiples
Smith & Nephew PLC
Glance View
Smith & Nephew PLC, a name synonymous with innovation in the medical technology sphere, began its journey in the late 19th century in the quaint city of Kingston upon Hull, England. This humble pharmaceutical shop evolved over time into a global leader in medical devices, driven by a commitment to improve people's quality of life through pioneering healthcare solutions. Today, the company stands as a key player in three core sectors: orthopedics, advanced wound management, and sports medicine. By focusing on these specialized areas, Smith & Nephew has set itself apart, effectively addressing the complex challenges faced by aging populations and a rising demand for minimally invasive treatments. Revenue streams pour in from their innovative products, which cater to both healthcare professionals and patients worldwide. In orthopedics, they make significant headway with implants and instruments used in hip and knee replacements, essential solutions in addressing joint deterioration and injury. Their advanced wound management division tackles issues from chronic wounds to burns, supplying dressings and delivery systems designed for optimal healing. Meanwhile, the sports medicine segment contributes by offering arthroscopy and enabling technologies, crucial for athletic injury prevention and recovery. By maintaining a strong pipeline of research and development initiatives, Smith & Nephew continues to enhance its offerings, pushing the envelope in medical technology and consequently fortifying its financial foundation.
